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Abstract: Schizophrenia is a chronic syndrome involving different clinical dimensions,
and causes signiﬁcant disability with a negative impact on the quality of life of patients
and their caregivers. Current guidelines for the treatment of schizophrenia focus on
maximizing a patient’s adaptive functioning and quality of life in a recovery-oriented
approach that encourages active collaboration among patients, caregivers, and mental
health professionals to design and manage a customized and comprehensive care plan.
In the present study, a panel of experts (psychiatrists, psychologists, nurse, and social
worker) gathered to review and explore the need for contemporary use of second-
generation antipsychotic long-acting injectables (SGA LAIs) in “recovery-oriented” and
“patient-centered” care of schizophrenia. Starting from the available data and from
sharing personal attitudes and experiences, the panel selected three clinical dimensions
considered useful in characterizing each patient: phase of disease, adherence to treat-
ment, and level of functioning. For each clinical dimension, perspectives of patients
and caregivers with regard to needs, expectations, and personal experiences were
reviewed and the role of SGA LAIs in achieving shared goals examined. The experts
concluded that from today’s modern perspectives, SGA-LAIs may play an important
role in breaking the spiral of desocialization and functional decline in schizophrenia,
thus favoring the recovery process.
Keywords: long-acting injections, antipsychotic, schizophrenia, quality of life, subjective
well-being, recovery
Introduction
Schizophrenia is a chronic psychiatric syndrome involving different clinical dimen-
sions. Positive symptoms (eg, hallucinations, delusions) occur together with nega-
tive symptoms (eg, alogia, blunted affect), along with disorganization of speech and
behavior and impairment of cognitive and executive functions.1 All these symptoms
cause impairment of personal, social, and occupational skills, with profound nega-
tive impact on the patient’s quality of life (QoL).2–4 Primary goals in the manage-
ment of schizophrenia include not only achieving short- and long-term clinical
remission but also maintaining physical and mental functioning while improving
QoL and promoting the patient’s recovery.5,6 Indeed, key guidelines for the treat-
ment of schizophrenia focus on maximizing QoL and adaptive functioning, as well
as assisting patients in attaining personal life goals (eg, in employment, housing,
and personal relationships).7,8
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In this regard, recovery has been deﬁned as
a multidimensional construct comprising two sets of out-
comes, belonging to either the “objective” or the “subjec-
tive” domain.9 Objective clinical recovery is deﬁned by
symptom severity and level of functioning, whereas sub-
jective personal recovery refers to the patient’s QoL, self-
conﬁdence, future hopes, willingness to ask for help, reli-
ance on others, and no domination by symptoms. The two
dimensions are mutually linked, eg, better cognitive func-
tioning leads to better social integration and lower rates of
anxiety and depression.10 Therefore, in the process of
extending the deﬁnition of remission and recovery, sub-
jective outcomes have been increasingly valued as impor-
tant components of full remission, encompassing clinical
and functional remission together with adequate subjective
well-being and QoL.11 Moreover, the fact that the avail-
able evidence indicates that personal recovery has
a salutogenic effect further supports the importance of
patient-centered care in schizophrenia.12,13
A recovery-oriented approach involves different profes-
sionals to allow for integrated exchange of expertise.14 This
may require a team synergistically working toward the same
aim, ie, to help the patient and increase his/her QoL.5
Including patients and their caregivers in the decision-
making process can enhance insight into the disease, with
a clear expectation of better treatments and outcomes.15
People with schizophrenia are encouraged to be part of
the management team and to participate constantly in deci-
sions regarding treatment.16 Despite their symptoms,
patients can still provide information on their state of health
that caregivers can supplement and contextualize.17
Given these considerations, it is surprising that
a thorough evaluation of patients’ and caregivers’ attitudes
toward illness, as well as their preferences regarding phar-
macological and nonpharmacological treatments, has
received little scientiﬁc attention.18 There are likely several
reasons for this, including the fact that most psychiatrists
believe that patients with schizophrenia are not reliable in
assessing their subjective well-being. Part of the scarce
clinical and scientiﬁc interest in the patient’s perspective
may also be due to the tendency of psychiatrists to over-
estimate how well they know their patients, and thus to
underestimate the value of asking their point of view.18,19
Conversely, from a clinical perspective, focusing on
patient’s subjective experience offers precious insight into
each individual’s personal recovery and into his or her
strengths, weaknesses, wishes, activities, and preferences.
The personal meaning that each person attributes to his/her
illness and to the treatment received within his/her life con-
text is central, to address an optimal recovery.20
The increasing interest in patients’ attitudes toward
treatment is conﬁrmed by the integration of patient-
reported outcomes into the process of developing and
testing new antipsychotic medications.21 Understanding
the attitudes of patients and caregivers can thus represent
a valuable asset in tailoring treatment to expressed
needs, and has the potential to improve the therapeutic
alliance and medication adherence, thereby enhancing
long-term prognosis.22 The recent development
of second-generation antipsychotic long-acting
injectables (SGA LAIs) has increased the number of
options available to personalize pharmacological treat-
ment of schizophrenia.23 SGA LAIs are likely to ﬁt well
into the long-term, comprehensive, multimodal treatment
plans that are recommended today for schizophrenia in
Italy and in other countries.23 Linking the use of SGA
LAIs to the goals of patients and caregivers may con-
tribute signiﬁcantly to achieving remission and
recovery.24,25 In this regard, previous evidence suggests
that the use of SGA LAIs is an optimal strategy to
address the subjective core of a satisfying recovery
from schizophrenia. In particular, maintenance treatment
with SGA LAIs seems to be related to signiﬁcant
improvements in subjective well-being, attitudes toward
treatment, and health-related QoL.25,26
In light of these considerations, themain aim of this paper
was to review and explore the effect of SGA LAIs on patient
and caregiver expectations of care, personal goals, and QoL.
Furthermore, the impact of SGA LAIs on the “recovery-
oriented” and “patient-centered” treatment of schizophrenia
was evaluated, eg, how SGA LAIs can affect the sharing of
therapeutic decisions, assessment of outcomes, and use of
mental health–service resources (eg, time management).
Toward this end, a panel of eleven experts gathered at
a consensus meeting (June 26, 2017 in Milan) with the aim
of representing the majority of mental health profes-
sionals (psychiatrist, psychologist, nurse, social worker)
who treat patients with schizophrenia. The panel included
eight psychiatrists, a psychologist, a nurse and a social
worker. To be included in the panel, the experts had to have
at least 10 years of experience in hospital- or community-
based services. The consensus among participants was
reached through discussion during the meeting, followed by
email correspondence, and was based on the practical experi-
ence of the panel, as well as on a review of available
literature.
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A comprehensive literature search was performed using
the PubMed database for biomedical English-language litera-
ture. Multiple searches were conducted combining headings
and keywords for “long-acting injectable”, “antipsychotic”,
“schizophrenia”, “patient-centered”, “recovery”, “recovery-
oriented”, “health-related”, “quality of life”, and “subjective
well-being”.
Starting from the selected data and sharing of personal
attitudes and experiences, the panel selected three clinical
dimensions that they considered useful to characterize each
patient: phase of disease, adherence to treatment, and level
of functioning. For each clinical dimension, perspectives of
patients and caregivers with regard to needs, expectations,
and personal experiences were reviewed and the role of
SGA LAIs in achieving those speciﬁc goals examined.
Phase of disease
Each phase of schizophrenia, from the ﬁrst episode (FES) to
the chronic phase, corresponds to different sets of needs and
expectations about the disease and its treatment (Table 1).
This requires planning speciﬁc interventions that should be
recovery-oriented and aimed at promoting QoL.
First-episode schizophrenia
There is increasing consensus that the early phases of
psychosis represent a critical period for the treatment of
schizophrenia and for its long-term prognosis.27–30 The
clinical experience of the panel of experts is that patients
with FES often show poor awareness of their disorder. The
time between the onset of psychotic symptoms and the
beginning of treatment (perhaps triggered by disturbing
Table 1 Phase of disease: effects of SGA LAIs on patient and caregiver needs, expectations, and personal experiences
First-episode schizophrenia Chronic schizophrenia
Personal experiences Needs and expec-
tations (toward
illness and care)
Personal experiences Needs and expectations
(toward illness and care)
-Poor awareness/uncer-
tainty about the impact of
the illness
- Denial of the illness
-Skepticism of establishing
a therapeutic relationship/
receiving AP treatment
-Stress (for ﬁrst contact
with MHS, hospitalization,
ER presentations)
-Neurocognitive deﬁcits
-Hopes of returning to
normality/recovery
-Avoid illness engulf-
ment/self-
stigmatization
-Fewer treatment-
related adverse effects/
visits to MHS
-Greater treatment
satisfaction/SWB
-Depressive symptoms (for stronger perceived
stigma/greater insight about the illness)
-Self-harm, difﬁculties with personal relationships,
loss of self-esteem, and decreased QoL (for fre-
quent relapses, duration of illness)
-Stress (for emotional and ﬁnancial impact of fre-
quent relapses)
-Fewer relapses
-Improvement of social and work
functioning
-More information about treat-
ments and advantages/goals of psy-
chopharmacological treatment
-Social integration with speciﬁc
interventions
Effects of SGA LAIs Effects of SGA LAIs
● Better clinical outcome (eg, relapse reduction, fewer
positive symptoms) vs oral formulations
● Reduction of hospitalizations/treatment discontinua-
tions (lower level of stress and disease burden;
greater perceived normality and hope for recovery)
● Neuroprotective effect vs FGAs
● More favorable pharmacokinetics (better tolerability
and SWB; fewer treatment self-discontinuations)
● Reduction in treatment intensity (maintenance of
employment and social life, reduced need of fre-
quent visits to MHS)
● Less monitoring of treatment adherence (improved
therapeutic alliance; greater stability and family cli-
mate of normality)
● Long-term control of psychotic and affective symptoms
● Reduction in treatment intensity (more focus on life goals, better self-conﬁdence and
hope, limited stigma and self-stigma, better social and work functioning, reduction of
stress, greater involvement in personalized psychosocial interventions)
● Relapse reduction (better patient self-esteem)
● No unintentional or deliberate overdose (reduced risk of self-harm)
Abbreviations: AP, antipsychotic; FGAs, ﬁrst-generation antipsychotics; MHS, mental health services; QoL, quality of life; SGA LAIs, second-generation antipsychotics long-
acting injectable; SWB, subjective well-being.
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symptoms or social difﬁculties) is often characterized by
a sense of uncertainty of the patient about the impact of
the disease on his/her life and by his/her hopes of returning
to normality with no speciﬁc interventions. These early
expectations of FES patients are often reported by their
caregivers,31–33 and may lead them to refuse specialized
treatment to avoid stigmatization by self and others.31
Although young patients may recognize that they have
some kind of “problem”, their perception of its cause and
true nature is often very different from that of their psychia-
trists and is permeated by personal values. Most FES
patients cannot link difﬁculties at school or work to
a speciﬁc mental condition before receiving appropriate
specialized support aimed at helping them to cope with
the initial stages of illness and to adapt their lifestyle
appropriately.33,34 On the other hand, inadequate
encounters between psychiatric services and severely dis-
abled young patients may further exacerbate their “need” to
deny their state of illness and lead FES patients to become
skeptical about the possibility of establishing a therapeutic
relationship and receiving help. The ﬁrst contact with men-
tal health professionals can understandably be perceived as
a source of stress by patients and caregivers, especially in
cases of early hospitalization due to an acute episode.
In consideration of all of these aspects, it is necessary
to actively engage patients, starting with the very ﬁrst
contact with mental health services. This implies investing
time in listening and understanding the patient’s feelings
and values, in order to create a virtuous circle aimed at
achieving practical and individualized goals that can in
turn boost treatment adherence.31–33
With regard to adherence, it is well known that interrupt-
ing the use of antipsychotics in patients with a ﬁrst episode of
schizophrenia or schizoaffective disorder increases the risk
of recurrence by about ﬁvefold.35 Unfortunately, even when
patients with FES have responded to antipsychotic treatment
and achieved remission, their adherence to treatment is threa-
tened by a number of different issues:
● the need for antipsychotic maintenance treatment is
often put into doubt by patients who can become
(overtly or covertly) nonadherent36,37
● even from the early phases of illness, FES patients
may show signiﬁcant neurocognitive deﬁcits that can
negatively affect adherence to treatment38,39
● FES patients often show higher sensitivity to side
effects and negative subjective experiences of antipsy-
chotic treatment, with a negative impact on adherence22
All of these factors, which are related to the character-
istics of the disease at its onset and to the overall experi-
ence of treatment, can generate feelings of helplessness
and impotence in FES patients.40 This can cause what is
known as illness engulfment, or the feeling that the illness
completely deﬁnes the totality of the person’s being,
restricting all aspects of patient life, entirely redeﬁning
his/her concept of self and inducing self-stigmatization.41
Shared treatment goals and SGA LAIs in
ﬁrst-episode schizophrenia
As discussed, patients with FES need to avoid illness engulf-
ment and perceive themselves as “recovered” as soon as
possible. In this regard, the consistent, continuous, and stable
release of antipsychotic treatment granted by LAI formula-
tions has been associated with better clinical outcomes com-
pared to oral formulations, which include fewer relapses,
fewer positive symptoms, and better adherence.37 In particular,
the reduction of hospitalizations and presentations to the ER
represents a substantial advantage in terms of lower overall
level of stress, disease burden, and contact with specialist care,
providing advantages for the patient in terms of perceived
normality and hope for recovery (Table 1).42
Since initiating antipsychotic treatment in patients with
FES is associated with sustained cognitive improvement for
up to 2 years,43 a treatment plan with SGA LAIs may be of
signiﬁcant advantage in terms of neuroprotective effect,
especially compared to the use of ﬁrst-generation antipsy-
chotics (FGAs), with their recognized neurotoxicity.44
Substantial clinical evidence indicates that typical and aty-
pical antipsychotics have diverse effects on neuronal survi-
val and neurogenesis: while the former appear to reduce
neuroprotection in the brain, the latter increase the level of
BDNF and improve cell survival and neurogenesis.44
Another important point is that long-acting or
extended-release antipsychotics have a narrow peak-to-
trough ﬂuctuation index and are therefore believed to be
better tolerated than drugs with immediate-release
formulations.45 The more favorable pharmacokinetic pro-
ﬁle can be particularly convenient for patients in the early
stages of disease who are more sensitive to treatment-
related adverse effects.35,46,47 In fact, the use of SGA
LAIs makes intentional self-discontinuation of treatment
less frequent compared to oral formulations in patients
who have doubts about continuing with their medication
and are at risk of becoming nonadherent (something that is
crucial to avoid in FES patients).48
Pietrini et al Dovepress
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Early administration of LAI antipsychotics is also
reported to improve the therapeutic alliance, and the
reduced need for monitoring treatment adherence allows
the treatment team to focus on more patient-centered
issues (such as attitudes toward life, personal feelings,
and experiences) and facilitates the achievement of patient
personal goals.49 LAI formulations may also allow reduc-
tion of the frequency and intensity of family/caregiver
monitoring of patient treatment adherence and promote
a sense of greater stability that can restore a family climate
of “normality”.37 All these factors, pivoted on a stable
clinical condition, make patients better suited to integrated
rehabilitation programs,50 signiﬁcantly improving long-
term prognosis.37,51,52
Chronic schizophrenia
In the panel’s experience, patients with an extensive his-
tory of illness and multiple relapses are at risk of devel-
oping depressive symptoms, due to stronger perceived
stigma and acquisition of greater insight about the course
and prognosis of their illness. Frequent relapses and long
duration of illness can lead to increased risk of harming
themselves or others and difﬁculties with personal rela-
tionships, school, or work, and is associated with loss of
self-esteem and decreased QoL. Illness relapses also have
a negative emotional and ﬁnancial impact on families and
caregivers.51 Patients with chronic schizophrenia and their
caregivers often report a lack of information about possi-
ble treatments, as well as about the advantages and goals
of psychopharmacological treatment.18 They also express
a wish to be involved in speciﬁc interventions aimed at
social integration and in training and support actions for
family members.53
Shared treatment goals and SGA LAIs in
chronic schizophrenia
In patients with chronic schizophrenia with an extensive
history of illness and multiple relapses, SGA LAIs seem to
provide signiﬁcant beneﬁts in long-term control of both
psychotic and affective symptoms.54 During long-term
maintenance treatment, the availability of a low-frequency
regimen of antipsychotic administration, eg, with SGA
LAIs, can allow patients to focus on their life goals, foster
self-conﬁdence and hope, and limit the risks of stigma and
self-stigma. This can help patients to improve their social
and work functioning, while minimizing the risks of
relapse.55 The expected greater prevention of relapse with
LAI formulations may also improve patients’ self-esteem
during long-term management (Table 1).43
A treatment plan with monthly or trimonthly injections
of antipsychotic treatment may be preferable for many
patients, as it may be less cumbersome than biweekly
injections.56 In fact, increasing the time between injections
not only reduces psychological stress and injection-
associated pain but also reduces the burden of traveling
to the local outpatient clinic. In the treatment of later
stages of illness, SGA LAIs allow the patient to be more
involved in personalized psychosocial interventions,
because the overall complexity of the psychopharmacolo-
gical treatment regimen is reduced.57 This is important for
fostering greater involvement of patients in other interven-
tions that can provide better social integration, as well as
in training and support actions for their family and
caregivers.
Adherence to treatment
Nonadherence in schizophrenia should be destigmatized,
given that nonadherence is common even in nonpsychia-
tric illnesses.58 However, poor medication adherence in
schizophrenia is a complex phenomenon that is associated
with a number of factors.59 In addition to the disease itself,
other factors undoubtedly contribute to medication adher-
ence, such as personal features, comorbidities (eg, sub-
stance-use disorders), and treatment-related characteristics.
Treatment satisfaction correlates positively with adher-
ence to therapy,60 and several domains of treatment satis-
faction have been associated with the type and mode of
medication delivery. These include perceived effective-
ness, side effects, ease of treatment regimen, and
costs.61,62 The panel of experts reported that previous
negative experiences can contribute further to nonadher-
ence: compulsory admission to psychiatric clinics, com-
pulsory acute intramuscular antipsychotic injections,
previous exposure to higher-than-necessary antipsychotic
doses with associated extrapyramidal symptoms, and
negative subjective well-being. The experts broadly iden-
tiﬁed two types of adherence: full adherence and nonad-
herence. In the real world, of course, patients show
different levels of adherence between these two extremes.
SGA LAIs from the patient’s perspective
In other ﬁelds of medicine, LAI medications have been
perceived as technological progress that allows not only
addressing the issue of nonadherence but also a focus on
a patient’s treatment satisfaction and subjective well-
Dovepress Pietrini et al
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being.63 In the ﬁeld of psychiatry, greater use of LAI
antipsychotics might lead to similar advantages.25 In par-
ticular, the switch from oral to LAI antipsychotic main-
tenance treatment seems to induce a sustained
improvement in attitude toward the drug in patients with
schizophrenia.26
Several factors related to the type of delivery of LAI
antipsychotic formulations may promote better adherence.
Based on the panel’s experience, the switch from oral
antipsychotic to LAI formulations, from FGA-LAIs to
SGA-LAIs, and more recently from a monthly to a for-
mulation taken once every 3 months (eg, paliperidone
palmitate), can dramatically increase patient satisfaction
and retention in treatment. For example, the ﬂexibility
associated with a monthly LAI regimen, and even more
with once every 3 months (which allows a ±2-week ﬂex-
ible additional interval between doses), may be appre-
ciated by adherent patients, particularly younger ones,
who in the early phase of illness are able to maintain an
occupation, may be willing to travel, and may appreciate
the convenience of this formulation (Table 2).
Adherent patients
Fully adherent patients deserve delivery of treatment that
is as ﬂexible as possible. They typically do not need to be
seen often by mental health professionals (especially if
young, at early stages of disease, or with a preserved
level of functioning), and may feel constrained when tak-
ing pills in front of others. These patients would suffer
from the burden of frequent visits to a community mental
health center (which is typically open during working
hours, so that they have to leave from work). This latter
aspect is highly relevant for young persons in early stages
of disease and with full-time, competitive work.
The adherent patient expects treatment-related side
effects to be minimized. They often suffer from extrapyr-
amidal symptoms, weight gain, and sexual side effects,
and ask for better tolerability and subjective well-being
under medication.11,64–68 Negative subjective well-being
has been related with higher than 70% D2-receptor occu-
pancy in striatal and extrastriatal cerebral areas.69–74
Therefore, higher-than-necessary antipsychotic doses or
the concomitant use of multiple antipsychotics should be
avoided, as this may expose patients to high D2-receptor
occupancy and a reduction in perceived well-being and
treatment satisfaction.
Subjective well-being during antipsychotic treatment is
likely to be best achieved by using the lowest effective dose
of antipsychotics.75 Achieving subjective well-being under
treatment is important in patients with good adherence, as
well as in those who are not fully adherent. Different types
of medication delivery, such as LAI formulations, may help
clinicians to titrate the dose slowly to the lowest effective
one, while avoiding the risk of relapses.
SGA LAIs from the adherent patient’s
perspective
A potentially useful factor associated with SGA LAIs in
adherent patients (as well as in partially adherent and nonad-
herent patients) is reduction of treatment-related discomfort.
FGAs are associated with negative subjective well-being and
so-called neuroleptic dysphoria,76 both of which have been
related to D2-receptor occupancy >70%. As discussed, both
LAI and extended-release oral formulations are associated
with more favorable pharmacokinetics,45 possibly implying
that adequate plasma concentrations are more easily reached
and that D2 receptors are optimally occupied.
In addition to the pharmacokinetic advantages of once-
monthly SGA LAIs, some patients still report that they feel
somewhat “frozen” or “blocked” (mentally and/or physically)
in the ﬁrst few days after LAI administration. This transient
state may be related to an initial and rapid increase of the drug
plasma level and consequently to temporarily high occupancy
of D2 receptors. Similar transient negative subjective well-
being may be reported in the ﬁrst days after administration.
In such cases, the panel of experts believe that a formulation
once every 3 months (when available) might be preferred by
patients, as less frequent injections would reduce this initial
negative subjective experience. In some cases, fear of needles
and pain at the injection site may be additional issues for
which such a formulation may be favored. At the same time,
thanks to their pharmacokinetic stability, SGA LAIs can facil-
itate the titration to the lowest effective dose, thus limiting the
risk of overtreatment and promoting quaternary prevention.
This characteristic is very desirable, because it can reduce the
risk of both negative subjective experience of treatment and
dose-related side effects, thus improving overall the patient’s
acceptance of medication.77
Preliminary but consistent ﬁndings show that SGA
LAIs are preferred by adherent patients over FGAs and
their corresponding oral formulations, and are associated
with greater treatment satisfaction, subjective well-being,
and better QoL.25,78–83 In this regard, one aspect to con-
sider is that adherent patients may prefer the LAI option,
because it avoids the need for oral treatment, and thus they
Pietrini et al Dovepress
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are not constrained to take their medication in front of
others. This may be especially relevant in patients with
privacy concerns (eg, patients attending university who
live with other students). Less frequent injections, like
the use of a formulation once every 3 months, may also
be perceived by the patient as being “on the road to
recovery”. A reduction in treatment intensity may be asso-
ciated with hope, social acceptability, greater involvement
in life, and be highly appreciated by both patients and
caregivers. This may be particularly true for young ﬁrst-
episode patients with high levels of cognitive functioning
who are able to maintain employment, have a satisfying
social life, and travel. As mentioned, these patients do not
need frequent follow-up visits, and thus may ﬁnd an opti-
mal treatment strategy in SGA LAIs.
Partially adherent patients
In the clinical experience of the experts, the patient with
partial adherence is clearly in need of greater treatment
satisfaction. He/she is not only less prone to tolerate side
effects but also requires more effective treatment and
needs to be seen more often by mental health professionals
than the fully adherent patient. This patient often fails to
take medication appropriately because of the intrinsic
Table 2 Adherence to treatment: effects of SGA LAIs on patient and caregiver needs, expectations, and personal experiences
Adherent patients Partially adherent patients Nonadherent patients
Personal
experiences
Needs and
expectations
(toward ill-
ness and
care)
Personal
experiences
Needs and
expectations
(toward ill-
ness and
care)
Personal experiences Needs and
expectations
(toward ill-
ness and
care)
- Burden of frequent
visits to MHS
-Constraints of taking
pills in front of other
(eg, patients with
privacy concerns)
-Treatment dein-
tensiﬁcation
-Flexible delivery
of treatment
- Fewer treat-
ment-related SEs
-Greater treat-
ment satisfac-
tion/better SWB
- Prior negative experi-
ence with AP treat-
ments
-Frequent disputes with
caregivers about taking
pills every day/ more
than once a day
-More effective
treatment
- Need to be
seen more often
by MHS
-No need to dis-
cuss nonadher-
ence issues with
clinicians
-Fewer treat-
ment-related SEs
-Greater treat-
ment satisfaction
-Complete lack of insight
- Denial of illness
- Traumatic experience with
hospital admission and AP
treatment (eg, high dose with
signiﬁcant sedative action)
-Frequent disputes with care-
givers about taking pills
every day/ more once a day
-Reluctance to see the physician
- Appropriate AP
treatment
-Greater treat-
ment satisfac-
tion/better SWB
and QoL
Effects of SGA LAIs Effects of SGA LAIs Effects of SGA LAIs
● More favorable pharmacokinetic and
pharmacodynamic proﬁle (better toler-
ability, SWB, treatment satisfaction, and
QoL, lower risk of overtreatment, qua-
ternary prevention)
● Reduction in treatment intensity (better
hope and social acceptability, feeling of
being on the road to recovery, greater
involvement in life, no need of frequent
visits)
● No need to take pills in front of others
● More favorable pharmacokinetic and phar-
macodynamic proﬁle (better tolerability
and SWB)
● Better clinical outcome (eg, relapse reduc-
tion, fewer positive symptoms) vs oral
formulations
● Regular interactions between patient and
MHS (reassurance of to receiving the best
support possible)
● Less monitoring of treatment adherence
(more time used to evaluate patient’s
needs, greater empowerment)
● Reduction of disputes between patients
and caregivers about taking medication
● More favorable pharmacokinetic and pharmacody-
namic proﬁle (better tolerability and SWB)
● Guaranteed administration
● Earlier detection of possible relapses due to non-
adherence, which can be followed up quickly
● Wider window of opportunity for caregivers to
resume AP treatment, due to signiﬁcant delay in
time to relapse when treatment discontinued or
withdrawn
● Reduction of disputes between patients and care-
givers about taking medication
Abbreviations: AP, antipsychotic; MHS, mental health services; QoL, quality of life; SEs, side effects; SGA LAIs, second-generation long-acting injectable antipsychotics;
SWB, subjective well-being.
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symptoms of his/her illness. Typically, blaming these
patients for missing doses is not useful. It may also be
annoying for the patient to have family members remind-
ing them to take pills every day one or more times per day,
and having to spend time during follow-up visits discuss-
ing with the clinician treatment-nonadherence implications
(Table 2). For this type of patient, there is a clear need for
a treatment formulation that can address these issues.
SGA LAIs from the partially adherent
patient’s perspective
The better tolerability of LAI formulations and their greater
efﬁcacy represent a signiﬁcant advantage not only for fully
adherent patients but also for those who are only partially
adherent. This is especially important for the latter group, as
they usually ask for a more effective treatment with fewer
side effects. Improving efﬁcacy and tolerability of antipsy-
chotic treatment is also important for patients who are
completely nonadherent due to prior negative experiences
associated with a previous high-dose antipsychotic treat-
ment with signiﬁcant sedative action.
In patients with partial adherence, the use of SGA-LAIs
requires less adherence assessment, so more time can be used
to evaluate the patient’s individual needs, fostering greater
empowerment and willingness to follow the shared treatment
plan to achieve personalized goals.84 The regular schedule of
follow-up visits planned for patients under LAI treatment
seems to further to reassure the patient and his/her caregivers
that they are receiving the best support possible. The use of
SGA LAIs also has the potential to reduce disputes of
patients with family members/caregivers about adherence.
Such an advantage is particularly obvious in patients who are
partially adherent or completely nonadherent. SGA-LAI for-
mulations once every 3 months may amplify this advantage
by reducing injections to only four times a year.
Nonadherent patients
Most nonadherent patients are characterized by a complete
lack of insight. As a consequence, they have often had
previous negative experiences of traumatic compulsory
admissions to hospital and acute intramuscular antipsycho-
tic injections. For example, it might have been necessary
to control acute agitation with rapid tranquilization such
that they may have been administered strong sedatives or
even unnecessarily high doses of antipsychotics.
Furthermore, denial of illness often compromises
relationships with mental health professionals such that
the nonadherent patient is reluctant to see the treating
physician or general practitioner, thus rendering treatment
of comorbid conditions more difﬁcult. Nonetheless, family
and caregivers of nonadherent patients generally expect
treatment intervention and are often in open conﬂict with
the patient. Disputes about medication adherence often
compromise daily life and the patient’s family climate,
with a severe negative impact on his/her QoL.
SGA LAIs from the nonadherent patient’s
perspective
Consensus guidelines recommend considering LAI anti-
psychotics in patients who lack insight into their illness
and in patients with multiple relapses due to treatment
non-adherence.85 The use of SGA LAIs in non-adherent
patients may be of great clinical utility because it enables
clinicians to proactively detect early signs of possible
relapses, while evaluating the efﬁcacy of treatment and
need for changes in the treatment plan (Table 2).86
As said before, the use of SGA LAIs also has the
potential to reduce disputes of the patients with family
members/caregivers about adherence. Such an advantage
is particularly obvious in patients who are completely non-
adherent. LAI formulations may be preferred in non-
adherent patients when considering the signiﬁcant delay
in time to relapse when this treatment formulation is dis-
continued or withdrawn. In a study by Weiden et al, med-
ian time to relapse after discontinuation of oral
paliperidone, once-monthly paliperidone, and paliperidone
once-every-3-months was 58, 172 and 395 days,
respectively.87 Such a delay is likely to be appreciated by
a non-adherent patient’s family members/caregivers, as it
gives more time to persuade the patient to resume anti-
psychotic treatment. In fact, when asked whether they
would have preferred the patient to be switched from the
current oral antipsychotic formulation to a once-every
-3-months LAI formulation, 67.5% of caregivers of ﬁrst-
episode patients and 77.8% of multiple-episode patients
preferred the once-every-3-months formulation.88
Level of functioning
Life domains related to living independently, productive
activities, and social relations are often highly compro-
mised in patients with schizophrenia.89 Functional out-
comes of schizophrenia correlate with age of onset,
premorbid adaptation, duration of untreated psychosis,
and adherence to treatment. Functional impairment of
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patients with schizophrenia is only partly attributable to
the symptoms of the disorder: personal resources and other
aspects relating to the family and social context, stigma,
and self-discrimination often provide a crucial
contribution.89–92 In fact, although remission of symptoms
and reduced rate of relapses produce a positive impact on
a patient’s everyday life, this is frequently not sufﬁcient to
ensure the achievement of functional recovery, especially
in low-functioning cases.93,94
Independently of the level of functioning, the suffering
experienced by patients and caregivers is caused not only
by the disorder itself, but also by the disturbances in social
and relationship domains, in terms of marginalization,
exclusion, rejection, prejudice, and discrimination.95 The
negative stereotypes of weakness and disability add to
a sense of self-stigmatization of patients and caregivers,
with a negative impact on self-esteem, hope, empower-
ment, self-efﬁcacy, QoL, social cohesion, and treatment
adherence, thus impinging heavily on daily functioning.90
For this reason, in both low- and high-functioning patients,
educational support for patients and caregivers should aim
to overcome the feeling of being affected by an incurable
disease and to raise awareness on the implications of fail-
ing to comply with treatment.96 Especially when the
patient with schizophrenia has shown competency prior
to the onset of the disorder, the hope of clinical and
functional recovery should be fostered whenever possible.
Low-functioning patients
In early-onset patients and/or in those characterized by low
levels of premorbid adaptation, schizophrenia affects the
person during a crucial phase of his/her development,
when he/she has not yet consolidated the basic skills
required to take on traditional social roles. In these cases,
the prognosis is often markedly worse than in later onsets
of schizophrenia in which the person has got full or partial
social cohesion, a good level of education, social and
personal relationships, some degree of independence
from family, his/her own family, and a job.97
Early intervention is linked to a higher probability of
success since the psychological and behavioral mechan-
isms that promote low-functioning have not yet become
chronic. Recovery is undoubtedly more difﬁcult to achieve
in the long-term stages of the disease in which patients and
caregivers are resigned to chronically impaired levels of
functioning. At the same time, the expectations of low-
functioning patients with schizophrenia and their families
regarding recovery of previous functioning are more likely
to be satisﬁed when prompt and adequate treatment is
established.
Triggered by the belief that schizophrenia is a chronic
and incurable condition, the feeling of not being able to lead
a productive life convinces low-functioning patients and
their caregivers of the need for health and disability
beneﬁts.98 Another vicious circle can be activated wherein
patients are not prepared to give up their disability beneﬁts
for a job that is viewed as being less permanent and more
tedious, thus encouraging a regressive need for overall care.
As time passes, feelings of frustration and inability arises,
promoting a tendency to avoidance, isolation, and conﬁne-
ment with feelings of anger and self-blame (Table 3).
The added value of SGA LAIs in the
low-functioning patient
Access to pharmacologically effective and tolerable treat-
ments combined with antipsychotic formulations that
improve adherence, such as SGA LAIs, may be crucial
elements to guarantee a stable clinical condition in the
recovery process in low-functioning patients with
schizophrenia.99 As previously mentioned, each relapse
of schizophrenia leads to a progressive decrease of
patient’s level of functioning.84 Since LAI antipsychotics
have been shown to be associated with fewer relapses
compared to conventional oral formulations,37 one of the
added values of SGA LAIs may consist in preventing
functional decline.
SGA LAIs are also recommended as ﬁrst line treatment
of schizophrenia in patients with cognitive impairment and
poor functioning.85 The lesser negative impact of SGA-
LAIs on cognitive aspects of the schizophrenic syndrome
compared to FGA-LAIs can allow for more productive
involvement of the patient in activities related to rehabili-
tation. Furthermore, in low-functioning patients, the con-
sequent improvement in adherence with LAI
formulations,26 due to the simpliﬁcation of treatment,
may decrease the family burden related to the need for
constant monitoring of treatment adherence due to the fear
that inadequate treatment will lead to relapse (Table 3).
In the last few years, the role of SGA-LAIs in improv-
ing both functioning and QoL of patients with schizophre-
nia has been investigated.84,100–102 For example,
Carpiniello et al have recently showed in a literature
review that the use of paliperidone palmitate once every
3 months was associated with beneﬁts in PANSS total
scores, positive symptoms, uncontrolled hostility/
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excitement, and anxiety/depression, as well as progressive
improvement of personal and social functioning.99 In
a case-control study by Pietrini et al, antipsychotic main-
tenance treatment with an SGA-LAI was associated with
better improvements in the PANSS, DAI-10, health-related
QoL, and functioning in almost all areas of daily living
compared with maintenance treatment with the corre-
sponding oral formulation.25 Surprisingly, during the
same treatment period, the group of patients on an oral
formulation showed signiﬁcant worsening of health-
related QoL in the areas of emotional role and social
functioning.25 All of these aspects allow clinicians and
the management team to devote more efforts to psychoso-
cial interventions aimed at achieving functional recovery
regardless of the level of baseline functioning, minimizing
the time and resources needed to monitor treatment
adherence.
High-functioning patients
High-functioning patients with schizophrenia and their care-
givers may have poor awareness of the implications of non-
adherence to treatment and may tend to limit contact with
mental health services (which can be viewed as stigmatizing
or constantly exposing to the burden of a disabling illness).
In this regard, daily oral treatment forces patients to pay
constant attention to their disease and can make them feel
more ill, less “normal”, or less “free”. On the other hand,
a smaller number of treatment administrations seems to be
more acceptable for high-functioning patients. In these
cases, the absence of relevant functional impairment
together with the fear of intolerable side effects and negative
consequences on subjective well-being and functioning
might lead patients to inadequate treatment (Table 3).
The added value of SGA LAIs in the
high-functioning patient
Access to pharmacologically effective and tolerable
treatments combined with formulations that improve
treatment adherence, such as SGA LAIs, are often
sufﬁcient elements to ensure the achievement and
maintenance of recovery in high-functioning
patients.99 In high-functioning patients, SGA-LAIs
have an important supportive function in the process
of breaking the spiral of desocialization and favoring
the recovery process.103 As said earlier, treatment dein-
tensiﬁcation can give patients greater ﬂexibility and
freedom to live their own lives,52 thus improving
their overall QoL (Table 3).
Table 3 Level of functioning: effects of SGA LAIs on patient and caregiver needs, expectations, and personal experiences
Low-functioning patients High-functioning patients
Personal experiences Needs and expecta-
tions (toward illness
and care)
Personal experiences Needs and expecta-
tions (toward illness
and care)
-Feelings of frustration, anger, self-
blame, and inability to lead
a productive life
-Tendency to avoidance and isola-
tion
-Regressive need for overall care
-Recovery of previous func-
tioning
-Establishment of prompt
and adequate treatment
-Treatment de-intensiﬁcation
-Poor awareness of the implications of
nonadherence
-Stigmatization of oneself and MHS
-Constraints of taking daily oral treatment
(patients feel more ill, less “normal”, or less
“free“)
-Fewer treatment-related
SEs
-Greater treatment satisfac-
tion/SWB
-Treatment deintensiﬁcation
Effects of SGA LAIS Effects of SGA LAIs
● Better tolerability and reduced variations in symptom control
● Lower relapse rates vs oral APs (preventing functional decline)
● Less negative impact on cognitive aspects vs FGA-LAIs (more
productive involvement in activities related to rehabilitation)
● Progressive improvement of positive symptoms, uncontrolled
hostility/excitement, anxiety/depression, personal and social
functioning, health-related QoL
● Decreasing family burden for constant monitoring of treatment
adherence
● Supportive function in the process of breaking the spiral of desocialization
and favoring the recovery process
● Reduction in treatment intensity (greater ﬂexibility and freedom,
improved QoL, reduction of frequency of MHS visits)
● No need to take medication on a daily basis (attention moved to other
aspects of daily life, lower risk of stigmatization of oneself and others)
Abbreviations: APs, antipsychotics; MHS, mental health services; QoL, quality of life; SEs, side effects; SGA LAIs, second-generation long-acting injectable antipsychotics;
SWB, subjective well-being.
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A smaller number of treatment administrations can
reduce the frequency of specialist visits and contacts.
This beneﬁt is particularly evident for patients who tend
to stigmatize mental health services and who have poor
awareness of the implications of non-adherence to treat-
ment. As the patient is no longer called upon to take the
drug on a daily basis (and at pre-established times) and to
repeatedly face the burden of being affected by an invali-
dating illness, attention may be diverted from the disorder
and moved to other aspects of daily life, with a lower risk
of stigmatization of oneself and others.
Discussion and conclusions
Schizophrenia is a chronic syndrome involving different
clinical dimensions and causing signiﬁcant functional
impairment with negative impact on QoL of patients and
caregivers.2–4 Current key guidelines for the treatment of
schizophrenia focus on maximizing patient’s adaptive
functioning and QoL in a recovery-oriented approach.7,8
A recovery-oriented treatment team should involve differ-
ent mental health professionals and include both patients
and caregivers in the decision-making process.14,15 Such
patient-centered psychiatric care encourages the active
collaboration between patients, families, and providers to
design and manage a customized and comprehensive care
plan.104
In this regard, “modern” use of SGA LAIs is likely to
ﬁt well into patient-centered treatment plans for
schizophrenia.23 In fact, the available evidence underlines
the better tolerability of SGA LAIs vs oral SGA,26,105,106
oral FGA,21 and ﬁrst-generation depot formulations.107
Beyond their efﬁcacy and tolerability proﬁle, other
advantages of SGA LAIs that can be appreciated, in
terms of subjective well-being, attitudes towards treat-
ment, and QoL, are probably due to their unique pharma-
cokinetic and pharmacodynamic proﬁle (ie, allow to
control titration to effective dose, to steady plasma drug
levels, to avoid ﬁrst-pass metabolism, and guarantee deliv-
ery of medication108), as well as to other individual and
environmental factors (ie, not having to take pills may
increase social adaptation, autonomy, and may reduce
stigma; periodic treatment monitoring may improve ther-
apeutic alliance, etc.).59 For these reasons, we think that
SGA LAIs can be seen as an increasingly valuable option
to improve compliance and a wide range of other clinical
and social outcomes.100,108–110
In the present study, a panel of experts (including
psychiatrists, psychologist, nurse and social worker)
gathered to review and explore the need for up-to-date
use of SGA LAIs in “recovery-oriented” and “patient-
centered” care of schizophrenia. First of all, the panel
participants agreed that the better clinical outcomes of
SGA LAIs compared to oral antipsychotics in terms of
fewer relapses, hospitalizations, and presentations to the
ER37 may signiﬁcantly lower patient’s and caregiver’s
overall level of stress, disease burden, and medicalization,
and increase perceived normality.42
Although this may be valid in all stages of disease and
at any level of functional impairment, this is particularly
important in the early phases of the disease. In fact, since
each relapse of schizophrenia leads to a progressive
decrease of the patient’s level of functioning,84 one of
the added values of SGA LAIs in recovery-oriented treat-
ment of schizophrenia consists of preventing functional
decline and minimizing the patient’s disability.
Each relapse has a negative impact on caregivers of
patient’s with schizophrenia, especially of those with
a long history of illness.51 These patients must not only
be involved in speciﬁc interventions aimed at social inte-
gration, but also in training and support programs for their
family members.53 In the opinion of the expert panel, the
low frequency of administration of SGA LAIs in later
stages of schizophrenia may allow patients and caregivers
to be more involved in recovery-oriented psychosocial
interventions and support actions.57 In the participants’
experience, schizophrenic patients are at increased risk of
developing depressive symptoms. However, SGA LAIs
seem to provide signiﬁcant beneﬁts in long-term control
of both psychotic and affective symptoms.54
Unfortunately, adherence to treatment of patients with
schizophrenia is often threatened by overt or covert non-
adherence,36,37 signiﬁcant cognitive symptoms,38,39 and
treatment-related side effects.22 However, the early admin-
istration of SGA LAIs is reported to improve therapeutic
alliance49 and cognitive functioning,43 as well as minimize
treatment-related adverse effects.35,46,47 In this regard, the
panel of experts agreed that LAI formulations should be
preferred in non-adherent patients, especially considering
the signiﬁcant delay in the time to relapse when this
treatment formulation is discontinued or withdrawn. Such
a delay is likely to be appreciated by family members/
caregivers of non-adherent patients, as it gives more time
to persuade the patient to resume antipsychotic
treatment.88 The reduced need of monitoring treatment
adherence provides the following advantages: on one
hand, the treatment team can focus on the patient’s
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personal goals with a consequent improvement of thera-
peutic alliance;49 on the other hand, patients and care-
givers can reduce disputes about medication adherence,
which may lead them to feel a sense of greater stability
that can consequently restore a family climate of
“normality”.37
The panel of experts also underlined how less frequent
long-acting antipsychotic injections, for example with the
use of a once-every-3-months formulation, may also be
perceived by the patient as being “on the road to recov-
ery”. In other terms, a reduction in treatment intensity may
be associated with hope, improved social acceptability,
limited risk of stigma and self-stigma, and greater involve-
ment in daily life activities, thus being highly appreciated
by both patients and caregivers.
In the present study, the panel of experts recommended
SGA LAIs as a ﬁrst line treatment of schizophrenia in
patients with cognitive impairment and poor functioning,
since the lesser negative impact of SGA-LAIs on cognitive
symptoms compared to FGA-LAIs allow for more produc-
tive involvement of the patient in rehabilitation
activities.85 At the same time, all patients with schizophre-
nia (especially those with FES or good baseline level of
functioning) expect treatment-related side effects to be
minimized.11,64–68 The experts suggested that
a potentially useful factor associated with SGA LAIs is
reduction of treatment-related discomfort. In fact, SGA
LAIs seem to have more favorable pharmacokinetics com-
pared to other antipsychotic formulations,45 possibly
because adequate plasma concentrations are more easily
reached and that D2 receptors are optimally occupied. At
the same time, thanks to their pharmacokinetic stability,
SGA LAIs can facilitate the titration to the lowest effective
dose, thus limiting the risk of overtreatment and promoting
quaternary prevention.
A once-every-3-months LAI formulation (when avail-
able) might also be preferred over a once-monthly one for
patients who refer a negative subjective experience of
antipsychotic treatment in the ﬁrst days after the injection,
as well as for those patients who fear needles.
In conclusion, all of the mentioned actions, pivoted on
a stable clinical condition, make patients with schizophre-
nia better suited to integrated rehabilitation programs,50
signiﬁcantly improving their long-term prognosis.37,51,52
Considered in a contemporary perspective, SGA-LAIs
have an important supportive function in the process of
breaking the spiral of de-socialization and functional
decline in schizophrenia, favoring the recovery
process.103 In fact, treatment deintensiﬁcation can give
patients greater ﬂexibility and freedom for living their
own lives,52 thus improving their overall QoL.
Patient- and caregiver-centered care of schizophrenia,
together with a modern use of SGA LAIs, may allow
clinicians and other mental health professionals to devote
more efforts to psychosocial interventions aimed at achiev-
ing recovery and minimizing the time and resources spent
to monitor treatment adherence.
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